Key result
Pre-PCI patent infarct artery linked to ~41% fewer 30-day deaths or reinfarctions vs occluded vessels.
Why the study?
It is unknown whether the association between early infarct-related artery patency and improved outcomes persists in contemporary practice with pre-hospital treatment, novel P2Y12 inhibitors, and drug-eluting stents.
Does early infarct-related artery patency before primary percutaneous coronary intervention improve 30-day outcomes in patients with ST-segment elevation myocardial infarction?
Cohort (n=1,863)
Yes
Does early infarct-related artery patency before primary percutaneous coronary intervention improve 30-day outcomes in patients with ST-segment elevation myocardial infarction?
Absolute Event Rate: 2.7% vs 4.6%
p-value: p=0.039
Early infarct-related artery patency before primary PCI in STEMI patients remains associated with higher procedural success and improved 30-day clinical outcomes in the contemporary era.
No takes yet. Share an insight, caveat, or question.
Pre-PCI patency may aid STEMI risk stratification; leaves open whether it is causal or a marker for better outcomes.
Rakowski et al. (2017) conducted a cohort in ST-segment elevation myocardial infarction (n=1,863). Patent infarct-related artery before percutaneous coronary intervention (TIMI flow 2/3) vs. Non-patent infarct-related artery (TIMI flow 0/1) was evaluated on Composite of death or myocardial infarction at 30 days (p=0.039). A patent infarct-related artery before primary percutaneous coronary intervention was associated with a lower 30-day rate of death or myocardial infarction compared to TIMI flow 0/1 (2.7% vs 4.6%; p=0.039).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: